Dental News - Novalar enters licence agreement for launching OraVerse in Germany

Search Dental Tribune

Novalar enters licence agreement for launching OraVerse in Germany

OraVerse injections reverses anesthesia after oral surgery and periodontal treatment. (DTI/Photo Michael Jung)
Daniel Zimmermann, DTI

Daniel Zimmermann, DTI

Fri. 5 March 2010

save

NEW YORK, USA/LEIPZIG, Germany: Novalar Pharmaceuticals has announced to have chosen Sanofi-Aventis Deutschland as exclusive distributor of their OraVerse anestethia reversal technology in Germany. Sanofi-Aventis, one of the leading German pharmaceutical companies, will also have the option to extend the license to other countries in Europe, both companies said. They intend to launch the product in early 2011.

OraVerse is a local anesthesia reversal agent that is said to accelerate the return of normal sensation and function following routine dental procedures. It is indicated for the reversal of soft tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is indicated for use only in adults and children 6 years of age or older and weighing at least 15 kg.

“As the largest dental market for local anesthetics in Europe, Germany represents a significant opportunity for the introduction of OraVerse,” said Donna Janson, President and Chief Executive Officer at Novalar. “Sanofi-Aventis do not only bring strong brand recognition and expertise in the European regulatory process but also demonstrated success in the dental industry. Their commercial network of will enable rapid penetration and reach into the target market.”

She added that applications for Marketing Authorization in several European countries will be submitted shortly.

To post a reply please login or register
advertisement
advertisement